What Xeris Biopharma Holdings, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 11 | 35 |
| Total trades | 12 | 70 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 22,365 | 1,428,702 |
| Disposed | 168,332 | 1,670,493 |
| Net activity | −145,967 | −241,791 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| McCulloch Kevin | See Remarks | Nov 05 | Open-market sale · S | −25,000 | $12.49 | −$312K | 1,559,208 |
| McCulloch Kevin | See Remarks | Nov 02 | Open-market sale · S | −15,000 | $10.23 | −$153K | 1,584,208 |
| Pieper Steven | See Remarks | Nov 02 | Open-market sale · S | −5,000 | $10.23 | −$51.2K | 1,346,053 |
| Taddese Menassie | Director | Nov 02 | Grant / award · A | +22,365 | — | — | 22,365 |
| Hecht Beth | See Remarks | Nov 02 | Open-market sale · S | −25,000 | $10.23 | −$256K | 1,086,130 |
| Hecht Beth | See Remarks | Oct 01 | Open-market sale · S | −16,666 | $9.41 | −$157K | 1,111,130 |
| McCulloch Kevin | See Remarks | Oct 01 | Open-market sale · S | −15,000 | $9.41 | −$141K | 1,599,208 |
| Pieper Steven | See Remarks | Oct 01 | Open-market sale · S | −5,000 | $9.41 | −$47K | 1,351,053 |
| McCulloch Kevin | See Remarks | Sep 28 | Open-market sale · S | −25,000 | $10.00 | −$250K | 1,614,208 |
| Hecht Beth | See Remarks | Sep 01 | Open-market sale · S | −16,666 | $8.49 | −$141K | 1,127,796 |
| Pieper Steven | See Remarks | Sep 01 | Open-market sale · S | −5,000 | $8.50 | −$42.5K | 1,356,053 |
| McCulloch Kevin | See Remarks | Sep 01 | Open-market sale · S | −15,000 | $8.49 | −$127K | 1,639,208 |
| Pieper Steven | See Remarks | Aug 12 | Open-market sale · S | −5,000 | $8.50 | −$42.5K | 1,361,053 |
| Hecht Beth | See Remarks | Aug 03 | Open-market sale · S | −16,666 | $8.01 | −$134K | 1,144,462 |
| McCulloch Kevin | See Remarks | Aug 03 | Open-market sale · S | −15,000 | $8.02 | −$120K | 1,676,126 |
| McCulloch Kevin | See Remarks | Aug 01 | Withheld — tax / exercise cost · F | −21,918 | $8.08 | −$177K | 1,654,208 |
| Shannon John Patrick Jr | See Remarks | Aug 01 | Withheld — tax / exercise cost · F | −36,645 | $8.08 | −$296K | 2,898,933 |
| Pieper Steven | See Remarks | Jul 07 | Open-market sale · S | −27,600 | $8.52 | −$235K | 1,366,053 |
| Pieper Steven | See Remarks | Jul 06 | Open-market sale · S | −17,400 | $8.50 | −$148K | 1,393,653 |
| Kreher Nerissa | Director | Jul 01 | Grant / award · A | +33,582 | — | — | 33,582 |
Loading...